Edgewise Therapeutics, Inc.
EWTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001710072
In the last 90 days, Edgewise Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.82B in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Edgewise Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 46 | 48 | +2 |
| Shares | 47.9M | 48.0M | +161.0K (+0.3%) |
| Value | $1.03B | $795.8M | −$232.6M (−22.6%) |
New holders (4)
Institutions that held Edgewise Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| State of Wisconsin Investment Board | 16,000 | $266.0K | 0.00% |
| Parametric Portfolio Associates LLC | 10,629 | $176.0K | 0.00% |
| Nisa Investment Advisors, LLC | 10,257 | $170.0K | 0.00% |
| Bank of America Corp | 2,740 | $46.0K | 0.00% |
Sold out (2)
Institutions that held Edgewise Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Pinz Capital Management, LP | 8,705 | $186.0K |
| UBS Group AG | 868 | $19.0K |